Search Results

You are looking at 101 - 110 of 840 items for :

  • Refine by Access: All x
Clear All
Full access

Postconsolidation Maintenance and Monitoring in Patients With Acute Promyelocytic Leukemia

Chezi Ganzel, Dan Douer, and Martin S. Tallman

Era ATO is considered the most potent anti-APL agent. Its use, which was traditionally reserved for patients experiencing relapse, has expanded and become more a part of induction-consolidation therapy. 15 , 16 Recently, primary results of the APL

Full access

A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer

Kazuki Sudo, Xuemei Wang, Lianchun Xiao, Roopma Wadhwa, Hironori Shiozaki, Elena Elimova, David C. Rice, Jeffrey H. Lee, Brian Weston, Manoop S. Bhutani, Adarsh Hiremath, Nikolaos Charalampakis, Ritsuko Komaki, Mariela A. Blum, Stephen G. Swisher, Dipen M. Maru, Heath D. Skinner, Jeana L. Garris, Jane E. Rogers, Wayne L. Hofstetter, and Jaffer A. Ajani

Background Among patients with localized esophageal cancer (LEC), 35% or more develop distant metastases (DM) as first relapse, most in the first 24 months after local therapy. 1 Worldwide, yearly new cases of esophageal cancer are estimated

Full access

Management of Extramedullary Leukemia as a Presentation of Acute Myeloid Leukemia

Samuel J. Slomowitz and Paul J. Shami

, chloroma , or myeloblastoma ), leukemia cutis (LC), and central nervous system (CNS) disease. Extramedullary disease at presentation or relapse can pose unique clinical problems. In general, the basic principles of systemic therapy remain the same. The

Full access

Improving Health Equity and Reducing Disparities in Pediatric and Adolescent/Young Adult Oncology: In Support of Clinical Practice Guidelines

Justine M. Kahn and Melissa Beauchemin

– 3 Hodgkin lymphoma (HL) represents an ideal paradigm for understanding cancer disparities, because successful treatments are well established in both the up-front and relapse treatment settings. Today, 5-year overall survival (OS) rates for children

Full access

Chimeric Antigen Receptor T-Cell Therapy

Ndiya Ogba, Nicole M. Arwood, Nancy L. Bartlett, Mara Bloom, Patrick Brown, Christine Brown, Elizabeth Lihua Budde, Robert Carlson, Stephanie Farnia, Terry J. Fry, Morgan Garber, Rebecca A. Gardner, Lauren Gurschick, Patricia Kropf, Jeff J. Reitan, Craig Sauter, Bijal Shah, Elizabeth J. Shpall, and Steven T. Rosen

later. 4 , 11 , 12 CD19 CAR T-Cell Therapy and Disease Management Leukemias Prognosis and overall survival (OS) rates in adult and pediatric patients with relapsed and refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. 13 – 15

Full access

Chemotherapy in the Management of Osteosarcoma and Ewing's Sarcoma

Scott M. Schuetze

. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity . N Engl J Med 1986 ; 314 : 1600 – 1606 . 19. Rosen G Caparros B Huvos AG . Preoperative chemotherapy for osteogenic sarcoma

Full access

Monitoring Chronic Myelogenous Leukemia in the Age of Tyrosine Kinase Inhibitors

Jerald P. Radich and Vivian Oehler

phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse . Leukemia 2005 ; 19 : 507 – 512 . 21. Merx K Muller MC Kreil S . Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic

Full access

Advancements in Radiation Techniques for Gastric Cancer

Matthew D. Callister and Leonard L. Gunderson

early locoregional relapse and attempt surgical resection and salvage. Local disease relapse was seen in 67% of patients, and 88% of these had a component of local or regional failure. In addition, 50% of peritoneal failures were localized to the

Full access

Defining and Managing High-Risk Multiple Myeloma: Current Concepts

Luciano J. Costa and Saad Z. Usmani

7 molecular subgroups of NDMM, 9 3 of which were described as having the highest risk of early relapse: the MMSET gene overexpression, MAF / MAFB overexpression, and proliferative gene overexpression subgroups. The Arkansas group also developed

Full access

Use of Biomarkers and Multigene Assays in Breast Cancer

Lee S. Schwartzberg

, they can stratify patients into lower and higher risk of later relapse between years 5 through 10 after diagnosis. The Breast Cancer Index also appears to have some predictive value for prolonged endocrine therapy. As a fundamental change, the latest